Obamacare Panel Announces Funding To Compare Hep C Rx, Diagnostics

A day after Gilead Sciences executives projected larger than expected discounts on hepatitis C medications, Obamacare's comparative-effectiveness research panel on Wednesday (Feb. 4) offered $50 million to compare diagnostics and drugs for hepatitis C, according to a release from the Patient-Centered Outcomes Research Institute. The hepatitis C funding is part of $138 million worth of research grants. The other $88 million funds a range of projects, $12 million of which is for rare diseases research. Hepatitis C drugs sparked a...